AGP Executive Report
Last update: 7 hours agoBiotech & Drug Development: BioVie says it’s in active talks with the FDA to finalize Phase 3 design for bezisterim in Parkinson’s, with a plan that may enrich patients showing inflammation-linked benefit. Pharvaris reports positive topline results from CHAPTER-3 for deucrictibant XR to prevent hereditary angioedema attacks, setting up planned marketing submissions in 2027. Clinical Evidence & Patient Care: TYLENOL with Naproxen is backed by new Phase 3 data presented at PAINWeek, supporting an OTC non-opioid option for post-surgical pain. Healthcare Access & Workforce: West Virginia will distribute $2.4M in rural health funds to expand employer-based worksite clinics. Quincy Valley Medical Center says its new facility is driving higher outpatient and emergency volumes after a year. Health Tech & Infrastructure: Spain’s SETT invests €7.2M in Deneb Medical to accelerate robotic, AI-enabled precision spine surgery. A UK hospital estates team is shortlisted for sustainability awards after a major decarbonisation push. Business & Policy Watch: A Kansas hospital system warns more patients are becoming uninsured as ACA premium supports expire, raising pressure for affordable coverage options. Research & Investment: Cloverleaf Bio closes a $33M seed round to advance RNA-based cancer therapeutics; BrainChild Bio raises $116M Series A for CAR T work in pediatric brainstem tumors.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.